Hester Biosciences, a leading player in the animal healthcare sector, has reported an impressive financial performance for Q2 FY25. The company’s consolidated results indicate strong growth in revenue and profitability, supported by efficient cost management and strategic expansion across its segments.
Q2 FY25 Key Highlights:
- Revenue from Operations increased by 18.8% year-on-year (YoY) to ₹83.69 crores from ₹70.45 crores in Q2 FY24.
- Profit After Tax (PAT) showed a significant surge of 107.4% YoY, rising to ₹8.39 crores from ₹4.04 crores in the corresponding quarter of the previous fiscal.
EBITDA Growth and Margins:
- EBITDA for Q2 FY25 reached ₹19.2 crores, reflecting a 45.4% YoY growth compared to ₹13.2 crores in Q2 FY24.
- EBITDA Margin improved significantly, standing at 22.94% in Q2 FY25, compared to 18.72% in Q2 FY24.
H1 FY25 Performance:
For the first six months ending on September 30, 2024:
- Revenue from Operations amounted to ₹146.97 crores, reflecting a steady increase compared to ₹146.78 crores in H1 FY24.
- Profit After Tax (PAT) for H1 FY25 surged by 34.1% YoY to ₹17.77 crores from ₹13.25 crores in H1 FY24.
